- I risultati di questo studio suggeriscono che i pazienti con pustolosi palmoplantare hanno un profilo di comorbilità sovrapponibile a quello dei soggetti con psoriasi volgare, ma non con quelli con disidrosi.
- Tuttavia, il rischio di comorbilità nei pazienti con pustolosi palmoplantare può essere significativamente differente rispetto ai soggetti con psoriasi volgare.
Palmoplantar pustulosis (PPP) has been reported to be accompanied by systemic conditions. However, the risks of comorbidities in patients with PPP have rarely been evaluated.
To assess the risks of comorbidities in patients with PPP compared with patients with psoriasis vulgaris or pompholyx.
Design, setting, and participants
This nationwide population-based cross-sectional study used data from the Korean National Health Insurance database and the National Health Screening Program collected from January 1, 2010, to December 31, 2019. Data were analyzed from July 1, 2020, to October 31, 2021. Korean patients diagnosed with PPP, psoriasis vulgaris, or pompholyx who visited a dermatologist between January 1, 2010, and December 31, 2019, were enrolled.
Presence of PPP.
Main outcomes and measures
The risks of comorbidities among patients with PPP vs patients with psoriasis vulgaris or pompholyx were evaluated using a multivariable logistic regression model.
A total of 37 399 patients with PPP (mean [SD] age, 48.98 [17.20] years; 51.7% female), 332 279 patients with psoriasis vulgaris (mean [SD] age, 47.29 [18.34] years; 58.7% male), and 365 415 patients with pompholyx (mean [SD] age, 40.92 [17.63] years; 57.4% female) were included in the analyses. Compared with patients with pompholyx, those with PPP had significantly higher risks of developing psoriasis vulgaris (adjusted odds ratio [aOR], 72.96; 95% CI, 68.19-78.05; p <0.001), psoriatic arthritis (aOR, 8.06; 95% CI, 6.55-9.92; p <0.001), ankylosing spondylitis (aOR, 1.91; 95% CI, 1.61-2.27; p <0.001), type 1 diabetes (aOR, 1.33; 95% CI, 1.16-1.52; p <0.001), type 2 diabetes (aOR, 1.33; 95% CI, 1.29-1.38; p <0.001), Graves disease (aOR, 1.25; 95% CI, 1.11-1.42; p <0.001), Crohn disease (aOR, 1.63; 95% CI, 1.11-2.40; p = 0.01), and vitiligo (aOR, 1.87; 95% CI, 1.65-2.12; p <0.001) after adjusting for demographic covariates. The risks of ankylosing spondylitis (aOR, 1.37; 95% CI, 1.16-1.62; p <0.001) and Graves disease (aOR, 1.40; 95% CI, 1.23-1.58; p <0.001) were significantly higher among patients with PPP vs psoriasis vulgaris. However, the risks of psoriatic arthritis (aOR, 0.54; 95% CI, 0.47-0.63; p <0.001), systemic lupus erythematosus (aOR, 0.67; 95% CI, 0.46-0.97; p = 0.04), Sjögren syndrome (aOR, 0.70; 95% CI, 0.50-0.96; p = 0.03), systemic sclerosis (aOR, 0.29; 95% CI, 0.11-0.77; p = 0.01), vitiligo (aOR, 0.53; 95% CI, 0.47-0.60; p <0.001), and alopecia areata (aOR, 0.88; 95% CI, 0.81-0.95; p = 0.001) were significantly lower among those with PPP vs psoriasis vulgaris.
Conclusions and relevance
The results of this cross-sectional study suggest that patients with PPP have an overlapping comorbidity profile with patients with psoriasis vulgaris but not patients with pompholyx. However, the risks of comorbidities among patients with PPP may be substantially different from those among patients with psoriasis vulgaris.